Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives

Bibliography

• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372(6505):425-32
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269(5223):543-6
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269(5223):540-43
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves Myalept to treat rare metabolic disease. 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm387060.htm
   Google Scholar
• Aegerion Pharmaceuticals I. Aegerion Pharmaceuticals Acquires Myalept™ From AstraZeneca. In: Aegerion Pharmaceuticals I, ed. 2014. Available from: http://ir.aegerion.com/releasedetail.cfm?ReleaseID=880952
   Google Scholar
• Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133(4):263-74
   PubMed Web of Science ®Google Scholar
• van Swieten MM, Pandit R, Adan RA, van der Plasse G. The neuroanatomical function of leptin in the hypothalamus. J Chem Neuroanat 2014;61-62:207-20
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kitamura T. Roles of FoxO1 and Sirt1 in the central regulation of food intake. Endocr J 2010;57(11):939-46
   PubMed Web of Science ®Google Scholar
• Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic beta-cell function. Metabolism 2011;60(12):1664-72
   PubMed Web of Science ®Google Scholar
• German JP, Thaler JP, Wisse BE, et al. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 2011;152(2):394-404
   PubMed Web of Science ®Google Scholar
• Minokoshi Y, Toda C, Okamoto S. Regulatory role of leptin in glucose and lipid metabolism in skeletal muscle. Indian J Endocrinol Metab 2012;16(Suppl 3):S562-8
   Google Scholar
• Cohen SL, Halaas JL, Friedman JM, et al. Human leptin characterization. Nature 1996;382(6592):589
   PubMed Web of Science ®Google Scholar
• Chou K, Perry CM. Metreleptin: first global approval. Drugs 2013;73(9):989-97
   PubMed Web of Science ®Google Scholar
• Park HK, Ahima RS. Leptin signaling. F1000prime reports 2014;6:73
   PubMedGoogle Scholar
• Benomar Y, Naour N, Aubourg A, et al. Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism. Endocrinology 2006;147(5):2550-6
   PubMed Web of Science ®Google Scholar
• Tang Y, Chen A. Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol 2010;161(5):1137-49
   PubMed Web of Science ®Google Scholar
• Wolsk E, Mygind H, Grondahl TS, et al. The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males. Am J Clin Nutr 2011;94(6):1533-44
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Brown RJ, Mari A, et al. Effects of leptin replacement therapy on pancreatic beta-cell function in patients with lipodystrophy. Diabetes Care 2014;37(4):1101-7
   PubMed Web of Science ®Google Scholar
• Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140(4):1630-8
   PubMed Web of Science ®Google Scholar
• Stan S, Levy E, Bendayan M, et al. Effect of human recombinant leptin on lipid handling by fully differentiated Caco-2 cells. FEBS Lett 2001;508(1):80-4
   PubMed Web of Science ®Google Scholar
• Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obesity reviews : an official. journal of the International Association for the Study of Obesity 2011;12(5):e315-23
   Google Scholar
• Rodríguez AJ, Neeman T, Giles AG, et al. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints. Arquivos Brasileiros de Endocrinologia & Metabologia 2014;58(8):783-97
   PubMed Web of Science ®Google Scholar
• Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nature reviews Endocrinology 2011;7(3):137-50
   PubMed Web of Science ®Google Scholar
• Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet 2008;47(11):753-64
   PubMed Web of Science ®Google Scholar
• Malloy MJ, Kane JP. Chapter 19. Disorders of Lipoprotein Metabolism. In: Gardner DG, Shoback D, eds. Greenspan’s Basic & Clinical Endocrinology. 9e. New York, NY: The McGraw-Hill Companies; 2011
   Google Scholar
• Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004;33(2):305-31
   PubMed Web of Science ®Google Scholar
• Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350(12):1220-34
   PubMed Web of Science ®Google Scholar
• Garg A. Clinical review: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011;96(11):3313-25
   PubMed Web of Science ®Google Scholar
• Garg A. Chapter 71. Lipodystrophy. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, eds. Fitzpatrick’s Dermatology in General Medicine. 8e. New York, NY: The McGraw-Hill Companies; 2012
   Google Scholar
• Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 2003;82(2):129-46
   PubMed Web of Science ®Google Scholar
• Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341(12):879-84
   PubMed Web of Science ®Google Scholar
• Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism 2015;64(1):146-56
   PubMed Web of Science ®Google Scholar
• Wabitsch M, Funcke J-B, Lennerz B, et al. Biologically Inactive Leptin and Early-Onset Extreme Obesity. New England Journal of Medicine 2015;372(1):48-54
   PubMed Web of Science ®Google Scholar
• Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. American journal of physiology Endocrinology and metabolism 2011;301(4):E567-84
   PubMed Web of Science ®Google Scholar
• Paz-Filho G, Esposito K, Hurwitz B, et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. American journal of physiology Endocrinology and metabolism 2008;295(6):E1401-8
   Google Scholar
• Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401(6748):73-6
   PubMed Web of Science ®Google Scholar
• Colombo C, Cutson JJ, Yamauchi T, et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002;51(9):2727-33
   PubMed Web of Science ®Google Scholar
• Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346(8):570-8
   PubMed Web of Science ®Google Scholar
• Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109(10):1345-50
   PubMed Web of Science ®Google Scholar
• Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54(7):1994-2002
   PubMed Web of Science ®Google Scholar
• Oral EA, Ruiz E, Andewelt A, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 2002;87(7):3110-17
   PubMed Web of Science ®Google Scholar
• Musso C, Cochran E, Javor E, et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism 2005;54(2):255-63
   PubMed Web of Science ®Google Scholar
• Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (Baltimore, Md) 2005;41(4):753-60
   PubMed Web of Science ®Google Scholar
• Oral EA, Javor ED, Ding L, et al. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab 2006;91(2):621-8
   PubMed Web of Science ®Google Scholar
• Sekhar RV, Jahoor F, Iyer D, et al. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism 2012;61(10):1395-403
   PubMed Web of Science ®Google Scholar
• Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr pract 2011;17(6):922-32
   PubMed Web of Science ®Google Scholar
• Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013;59(1):131-7
   PubMed Web of Science ®Google Scholar
• FDA Adverse Event Reporting System (FAERS). ed: U.S. Department of Health and Human Services 2014. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
   Google Scholar
• Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110(8):1093-103
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Jama 1999;282(16):1568-75. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
   PubMed Web of Science ®Google Scholar
• Deputy Division Director Summary Review of Myalept/metreleptin, Application number 125390Orig1s000. Center for Drug Evaluation and Research 2014:22
   Google Scholar
• Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010;53(1):27-35
   PubMed Web of Science ®Google Scholar
• Hall SW, Gillespie JJ, Tenczynski TF. Generalized lipodystrophy, scleroderma, and Hodgkin’s disease. Arch Intern Med 1978;138(8):1303-4
   PubMed Web of Science ®Google Scholar
• Yiannias JA, DiCaudo DJ, Maskin E. Peripheral T-cell lymphoma presenting as lipoatrophy and nodules. Int J Dermatol 2006;45(12):1415-19
   PubMed Web of Science ®Google Scholar
• Aslam A, Savage DB, Coulson IH. Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration. Int J Dermatol 2013;doi:10.1111/ijd.12185. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Moon HS, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011;60(6):1647-56
   PubMed Web of Science ®Google Scholar
• Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. European journal of endocrinology/ European Federation of Endocrine Societies 2011;165(2):249-54
   PubMed Web of Science ®Google Scholar
• Myalept (metreleptin for injection) Briefing Document. The Endocrinologic and Metabolic Drugs Advisory Committee. Food and Drug Administration Center for Drug Evaluation and Research 2013:312
   Google Scholar
• Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md) 2009;17(9):1736-43
   PubMed Web of Science ®Google Scholar
• Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 2004;89(7):3199-207
   PubMed Web of Science ®Google Scholar
• Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab 2012;97(3):785-92
   PubMed Web of Science ®Google Scholar
• Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 2011;60(7):1045-9
   PubMed Web of Science ®Google Scholar
• Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91(7):2605-11
   PubMed Web of Science ®Google Scholar
• Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94(4):1137-44
   PubMed Web of Science ®Google Scholar
• Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med 2013;7(2):207-22
   PubMed Web of Science ®Google Scholar
• Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000;85(11):4003-9
   PubMed Web of Science ®Google Scholar
• Hukshorn CJ, van Dielen FM, Buurman WA, et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002;26(4):504-9
   PubMed Web of Science ®Google Scholar
• Mackintosh RM, Hirsch J. The effects of leptin administration in non-obese human subjects. Obes Res 2001;9(8):462-9
   PubMedGoogle Scholar
• Korner J, Conroy R, Febres G, et al. Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity (Silver Spring) 2013;21(5):951-6.doi:10.1002/oby.20433
   PubMed Web of Science ®Google Scholar
• Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proceedings of the National Academy of Sciences of the United States of America 2008 May 20;105(20):7257-62
   Google Scholar
• Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005;115(12):3579-86
   PubMed Web of Science ®Google Scholar
• Muller TD, Sullivan LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J pept Sci 2012;18(6):383-93
   PubMed Web of Science ®Google Scholar
• Yu Y, Wu Y, Szabo A, et al. Teasaponin reduces inflammation and central leptin resistance in diet-induced obese male mice. Endocrinology 2013;154(9):3130-40
   PubMed Web of Science ®Google Scholar
• Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012;122(1):153-62
   PubMed Web of Science ®Google Scholar
• de Git KC, Adan RA. Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obesity reviews : an official journal of the International Association for the Study of Obesity 2015 Jan 14
   Google Scholar
• Astra-Zeneca. Myalept Prescribing information. 2014
   Google Scholar
• Masuzaki H, Ogawa Y, Isse N, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995;44(7):855-8
   PubMed Web of Science ®Google Scholar
• Klein S, Coppack SW, Mohamed-Ali V, Landt M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996;45(7):984-7
   PubMed Web of Science ®Google Scholar
• Sobhani I, Bado A, Vissuzaine C, et al. Leptin secretion and leptin receptor in the human stomach. Gut 2000;47(2):178-83
   PubMed Web of Science ®Google Scholar
• Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-5
   PubMed Web of Science ®Google Scholar
• Sinha MK, Sturis J, Ohannesian J, et al. Ultradian oscillations of leptin secretion in humans. Biochem Biophys Res Commun 1996;228(3):733-8
   PubMed Web of Science ®Google Scholar
• Licinio J, Mantzoros C, Negrao AB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3(5):575-9
   PubMed Web of Science ®Google Scholar
• Shea SA, Hilton MF, Orlova C, et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005;90(5):2537-44
   PubMed Web of Science ®Google Scholar
• Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin. J Clin Invest 1996;Sep;15;98(6):1277-82
   PubMed Web of Science ®Google Scholar
• Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996;20(12):1120-6
   PubMed Web of Science ®Google Scholar
• Leinninger GM, Jo YH, Leshan RL, et al. Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metab 2009;10(2):89-98
   PubMed Web of Science ®Google Scholar
• Denroche HC, Huynh FK, Kieffer TJ. The role of leptin in glucose homeostasis. Journal of diabetes investigation 2012;3(2):115-29
   PubMed Web of Science ®Google Scholar
• Harris RB. Direct and indirect effects of leptin on adipocyte metabolism. Biochim Biophys Acta 2014;1842(3):414-23
   PubMed Web of Science ®Google Scholar
• Aegerion Pharmaceuticals I. Myalept (metreleptin) for injection. 2015. 1 January 2015. Available from: http://www.myalept.com [Last Accessed Date 2015 3 February]
   Google Scholar
• Medicine USNLo. Genetics Home Reference. 3/23/15 ed 2015
   Google Scholar
• Agarwal AK. Lysophospholipid acyltransferases: 1-acylglycerol-3-phosphate O-acyltransferases. From discovery to disease. Curr Opin Lipidol 2012;23(4):290-302
   PubMed Web of Science ®Google Scholar
• Talukder MU, Michelle Sim MF, O’Rahilly S, et al. Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Mol Metab 2015;Mar;4(3):199-209
   Google Scholar
• Wee K, Yang W, Sugii S, Han W. Towards a mechanistic understanding of lipodystrophy and seipin functions. Biosci Rep 2014;34:5
   PubMedGoogle Scholar
• Garg A, Agarwal AK. Caveolin-1: a new locus for human lipodystrophy. J Clin Endocrinol Metab 2008;93(4):1183-5
   PubMed Web of Science ®Google Scholar
• Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 2008;283(7):4314-22
   PubMed Web of Science ®Google Scholar
• Herbst KL, Tannock LR, Deeb SS, et al. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003;26(6):1819-24
   PubMed Web of Science ®Google Scholar
• Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet 2014;59(1):16-23
   PubMed Web of Science ®Google Scholar
• Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87(5):2395
   PubMed Web of Science ®Google Scholar
• Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004;89(10):4821-6
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004;89(9):4258-63
   PubMed Web of Science ®Google Scholar
• Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004;53(4):513-19
   PubMed Web of Science ®Google Scholar
• Park JY, Javor ED, Cochran EK, et al. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 2007;56(4):508-16
   PubMed Web of Science ®Google Scholar
• Christensen JD, Lungu AO, Cochran E, et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab 2014;99(8):E1493-500
   Google Scholar
• Squibb B-M. An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy. 2015
   Google Scholar
• Oral E. Clinical protocol to investigate the efficacy of recombinant human leptin (metreleptin) in nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) associated with lipodystrophy. university of michigan national institute of diabetes and digestive and kidney diseases (NIDDK). 2014
   Google Scholar
• (NIDDK) NIoDaDaKD. Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Bethesda, MD. 2014
   Google Scholar
• (NIDDK) NIoDaDaKD. Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy. National Library of Medicine (US): Bethesda, MD. 2014
   Google Scholar
• (NIDDK) NIoDaDaKD. Short-term Effects of Leptin in People With Lipodystrophy. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Bethesda, MD. 2014
   Google Scholar
• (NIDDK) NIoDaDaKD. Leptin to Treat Lipodystrophy. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Bethesda, MD. 2014
   Google Scholar
• Abhimanyu Garg UoTSMC. Therapeutic Approaches to HAART-Induced Lipodystrophy. University of Texas Southwestern Medical Center 2013
   Google Scholar
• Center BIDM. Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome. Beth Israel Deaconess Medical Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Amgen: Boston, MA: 2011
   Google Scholar
• Center UoTSM. Trial of Leptin Replacement Therapy in Patients With Lipodystrophy. University of Texas Southwestern Medical Center 2013
   Google Scholar